Circulating metabolites in progression to islet autoimmunity and type 1 diabetes
Conclusions/interpretationOur findings suggest that children who progress to type 1 diabetes have a unique metabolic profile, which is, however, altered with the appearance of islet autoantibodies. Our findings may assist with early prediction of the disease.
Conclusions: Our estimated rates of prevalence of GP in T1DM and T2DM indicate that GP is not a common clinical complication in these populations. Majority of EMRs that indicated a diagnosis of GP did not include any documentation of definitive diagnostic testing (EGD and/or GES).
ConclusionsCirculating TNFR-1 and TNFR-2 are independently associated with higher risk of renal disease progression, CVD events, and mortality in patients with diabetes and might contribute to the clinical risk assessment in the future.
AbstractPhysiological plasticity enables homeostasis to be maintained in biological systems, but when such allostasis fails, then disease can develop. In a new population-based study by Rolandsson et al (https://doi.org/10.1007/s00125-019-05016-3), autoimmunity, defined by an immunogenotype, predicted adult-onset non-insulin requiring diabetes. Type 1 diabetes is no longer viewed as a disease confined to children, with a significant proportion, maybe the majority, presenting in adulthood. Such cases masquerade as type 2 diabetes and their identification has clinical utility. Nevertheless, in this study, autoimmunity had a ...
ConclusionsFlash glucose monitoring may be an acceptable self-management tool to increase monitoring frequency in adolescents and young adults with type 1 diabetes and high-risk glycemic control, with the potential to improve long-term glycemic control. Initial support efforts should focus on practical strategies to prolong sensor wear and motivate frequent scanning as well as education on interpreting glucose data and making informed treatment decisions to maximize the benefits of this technology.
Researchers believe they may help restore normal immune function in adults with type 1 disease with injections of stem cells, enabling the pancreas to produce insulin.
W.L. Gore &Associates is setting its sights on helping to improve insulin therapy in patients with type 1 diabetes. To do this the Flagstaff, AZ-based company is investing in PhysioLogic Devices, a startup developing an implantable intraperitoneal insulin delivery system. The investment is set to provide supplemental funding to allow Elkton, MD-based PhysioLogic to reduce key challenges associated with implantable micropumps and actuators and enable the startup's development goals for the upcoming years. An essential part of the system that PhysioLogic is developing is an implanted catheter for intraperitoneal insulin ...
FRIDAY, Dec. 6, 2019 -- Preterm birth is associated with an increased risk for type 1 and type 2 diabetes from childhood into early and middle adulthood, according to a study published online Dec. 3 in Diabetologia. Casey Crump, M.D., from the Icahn...
(Medical University of South Carolina) MUSC researchers launch the first NIH-funded clinical trial in the United States using umbilical cord derived mesenchymal stem cells for the treatment of patients with new onset type 1 diabetes.
Infants born prematurely were at increased risk of both Type 1 and Type 2 diabetes in ensuing decades.
Nature Reviews Gastroenterology &Hepatology, Published online: 06 December 2019; doi:10.1038/s41575-019-0242-7An area of research suggests a role for microbiota in the pathogenesis of pancreatic diseases, such as pancreatitis, pancreatic cancer and type 1 diabetes mellitus. In this Perspectives, the authors examine the literature implicating microorganisms in diseases of the pancreas as well as the evidence of an inherent pancreatic microbiota.